
EC clears first treatment for high-risk smouldering multiple...
Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Newsletters and Deep Dive digital magazine
Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.
HHS Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove thimerosal from all flu vaccines in the US
Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
The FDA seems to have won its staring contest with Sarepta over shipments of Elevidys, as the company blinks and agrees to a pause from today.
Editor's Picks
Newsletters and Deep Dive
digital magazine